-transparent.png){kind=logo}
1. The human umbilical vein has been found to contract in response to bradykinin (BK) and desArg9BK. 2. The rank order of potency of agonists, in the presence of the B1 receptor antagonist Lys[Leu8]desArg9BK, is as follows: [Hyp3, Tyr(Me)8]BK (pD2 8.88) = [Hyp3]BK (pD2 8.86) = LysBK (pD2 8.81) > or = BK (pD2 8.60) >> [Aib7]BK (pD2 6.38) >> desArg9BK and LysdesArg9BK (inactive). 3. Hoe 140 (pA2 8.42) inhibits the effects of BK while other B2 receptor peptide antagonists are very weak and WIN 64338 is practically inactive. 4. Venoconstrictor responses to desArg9BK of fresh tissues increase with time during the in vitro incubation and reach a maximum after 4-6 h. The activity of Hoe 140 (pA2 5.48) is negligible against B1 receptor agonists. 5. When measured in the presence of the selective B2 receptor antagonist Hoe 140 (400 nM), the order of potency of kinin related peptides on the B1 receptor is Lys[desArg9]BK (pD2 8.60) > desArg9BK (pD2 6.69). BK, LysBK, [Hyp3]BK and other B2 receptor agonists are inactive. 6. The B1 receptor antagonist, Lys[Leu8]desArg9BK (pA2 7.99), inhibits the response of the human vein to B1 receptor agonists (LysdesArg9BK or desArg9BK), but do not alter the effect of BK. 7. The results summarized in this paper indicate that the human isolated umbilical vein is a sensitive preparation containing both B1 and B2 receptors. The human B2 receptor shows some similarity with that of the rabbit (at least for agonist potencies) and differs from the B2 receptor of the guinea-pig. Compared to the rabbit B1 receptor, the human B1 receptor shows low sensitivity to peptides that lack the N-terminal Lys.
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
February 1997,
European journal of pharmacology,
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
March 1989,
European journal of pharmacology,
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
December 1996,
British journal of pharmacology,
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
July 1985,
Archives internationales de pharmacodynamie et de therapie,
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
September 1998,
Pharmacological reviews,
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
July 1997,
Journal of cellular physiology,
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
February 1998,
The Journal of endocrinology,
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
August 2003,
British journal of pharmacology,
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
April 1995,
The Journal of biological chemistry,
F Gobeil, and
L H Pheng, and
I Badini, and
X K Nguyen-Le, and
A Pizard, and
A Rizzi, and
D Blouin, and
D Regoli
February 1992,
FEBS letters,
